\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBarcelona
Leitat, one of Spain's technology centres, Acció, the Catalan Agency for Business Competitiveness, and the Provincial Council of Barcelona bring together cities, start-ups, companies, universities and technology centres for 2 days of inspiring keynote talks, panel discussions, and networking opportunities through our Innovation Marketplace and targeted matchmaking for the upcoming City Mission and city-related CL5 Horizon Europe calls.
This on-site event organised with the support of the Enterprise Europe Network (EEN), the largest business support network worldwide.
Main topics are Buildings/built environment, Circular urban economy, Energy, Mobility, Zero pollution.
More information and registration: here
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Research Infrastructures Culture and society Climate, Energy, Mobility
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
